insights_auto
Why is ABVX down 4,16%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
84,15 €
arrow_downward
-4,16%(-3,65) 1D
1 հոկ, 17:39:38 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
86,90 €
High
87,30 €
Low
83,20 €
Mkt. cap
7,58 մլրդ
Avg. vol.
152,86 հզր
Volume
138,06 հզր
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,53 մլն
No. of employees
98
Open
86,90 €
High
87,30 €
Low
83,20 €
Mkt. cap
7,58 մլրդ
Avg. vol.
152,86 հզր
Volume
138,06 հզր
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,53 մլն
No. of employees
98
News stories
From web sources and news partners
WTAQ
·
37 րոպե առաջ
Moderna to join Nasdaq 100, replacing Warner Bros Discovery
Yahoo Finance
·
2 ժամ առաջ
Vylor Takes Corteva’s S&P 500 Seat, Twilio Set To Replace Warner Bros. Discovery — Both Stocks Rise After-Hours
OneSafe
·
42 րոպե առաջ
Evernorth's Nasdaq Arrival Signals a Paradigm Shift in XRP Investment
MarketWatch
·
4 ժամ առաջ
The stock market is anything but normal right now — and these charts show it
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded04 դեկ, 2013 թ.
Headquarters-
Sector-
Websiteabivax.com